Skinvisible Reports Q2 2026 Financial Results with Net Loss of $255,533

Skinvisible, Inc. reported its financial results for the second quarter and first half of 2026, revealing a net loss of $255,533 for the three months ended June 30, 2026, compared to a loss of $274,427 for the same period in 2025. For the six months ended June 30, 2026, the company recorded a net loss of $522,717, a slight improvement from the $555,432 loss reported in the prior year. Revenue remained unchanged at $5,000 for the three months and $10,000 for the six months, indicating stagnant sales performance amid ongoing operational challenges.

The company’s total assets decreased to $123,334 as of June 30, 2026, down from $127,567 at the end of 2025. Current liabilities increased to $5,536,429, compared to $5,017,945 at the end of the previous fiscal year, contributing to a working capital deficit of $5,503,128. Skinvisible's accumulated deficit has now reached $41,532,893 since its inception, raising concerns about its ability to continue as a going concern without securing additional funding.

In terms of operational developments, Skinvisible continues to focus on its patented polymer delivery system, Invisicare, which is designed for topical applications in various healthcare markets. The company is actively pursuing licensing agreements to monetize its product formulations, including recent collaborations with Quoin Pharmaceuticals and Ovation Science. These partnerships are expected to enhance revenue generation, particularly as Quoin progresses with clinical trials for its product QRX003, which utilizes Skinvisible's technology for treating Netherton Syndrome.

Despite the lack of revenue growth, Skinvisible has made strides in reducing operating expenses, which fell to $117,817 for the second quarter of 2026 from $141,237 in the same quarter of 2025. The company aims to further decrease costs while increasing its licensing revenue. However, it remains uncertain whether these efforts will be sufficient to achieve profitability in the near future. Management has indicated plans to seek additional financing through equity offerings and licensing agreements to support ongoing operations and product development.

Looking ahead, Skinvisible's management acknowledges the significant challenges it faces, including the need for capital to fund operations and the uncertainty surrounding its ability to generate sufficient revenue. The company is exploring new opportunities in large medical markets beyond dermatology, such as obesity treatments, which could provide additional avenues for growth. However, the success of these initiatives will depend on the company's ability to secure necessary funding and navigate the competitive landscape of the pharmaceutical and skincare industries.